Forum

Linda, I apologize for missing the last 2 weeks. I hurt myself 2 weeks ago and have been out of commision for awhile. My plan is to post the Spiritual Gems every Sunday evening so that you friends have them available for your midweek meeting the following week. I will make sure they are there this Sunday evening and will be consistant moving forward. Thank you for your patience.

I subscribed, but I have not seen any further weekly gems as expected.  Please advise.   Sister Bryan

Hello Friends, A new feature I started is providing a weekly PDF file called Spiritual Gems Study Notes. They will contain bible highlights that can be used for study and commenting during the Spiritual Gems part of the midweek meeting. These files will be posted weekly under the Documents section. You will need a monthly subscription in order to access these files. Monthly subscriptions will help Meekspace to continue providing a safe place for Jehovah's people to associate online. The subscription will also give subscribers full access to the forums so that you can post and comment on forum posts. As a sample I will be providing the first installment of Spiritual Gems Study Notes here.

Biosensors Market focused on drug discovery and development is projected to grow at an annualized rate of 9% during the period 2023-2035   In recent years, the use of biosensors in drug discovery has been on the rise, driven by several technological advancements and the growing demand for inexpensive and effective techniques for analyzing potential drug candidates Roots Analysis has announced the addition of “Biosensors Market: Focus on Drug Discovery and Drug Development, 2023 - 2035” report to its list of offerings. A number of drug developers are already using novel biosensors for various drug discovery applications to address the concerns associated with high rate of failures of drug development programs and requirement of high capital investments. As the adoption of biosensors, specifically for drug discovery, increases amongst innovators in the pharma and biopharma industry, lucrative opportunities are expected to be created for players engaged in the biosensors for drug discovery market.  Key Market Insights Currently, more than 80 biosensors are being developed by various stakeholders, across the world Majority of the biosensors (64%) engaged in this domain are optical biosensors, followed by electrochemical biosensors (25%), quartz crystal microbalance biosensors (5%) and thermal biosensors (5%). Close to 95% of the biosensors are used for lead identification step in drug discovery. Further, 15% of the biosensors claim to support all the steps in drug discovery. Get Detailed Report: https://www.rootsanalysis.com/reports/global-biosensors-market.html Over USD 1.2 billion invested in various domain focused initiatives, since 2018 Specifically, in 2021, industry players raised close to USD 600 billion. In addition, majority of the companies (66%) primarily received funding through venture capital rounds. Further, around 60% of the total funding instances were reported by players headquartered in the US. In recent years, several global events related to biosensors in drug discovery were organized Majority of the events related to biosensors in drug discovery were organized in Europe (45%). It is worth highlighting that the main agenda of these events was to discuss the development and challenges associated with the biosensors in drug discovery domain. 370+ patents related to biosensors in drug discovery have been granted / filed between 2018-2022 R&D activity related to biosensors in drug discovery is largely concentrated in North America, considering the fact that 70% of the total number of patents were filed in this region. In addition, most of the patents in this domain are granted patents (55%), followed by patent applications (44%). North America and Europe are anticipated to capture over 70% of the market share, by 2035 In addition, the market in Asia Pacific is likely to grow at a relatively faster pace (10%) in the long term. Further, in 2035, biosensors market for drug discovery applications for academic / research institutes is expected to capture the majority share (~60%) of the total market. Request for Customization @ https://www.rootsanalysis.com/reports/global-biosensors-market/request-customization.html Key Questions Answered Who are the key players engaged in the biosensors in drug discovery market? What is the relative competitiveness of different biosensors being developed for drug discovery applications? What are the key agenda items being discussed in various global events / conferences related to biosensors in drug discovery? What is the focus area of the ongoing research activity related to biosensors in drug discovery? How is the intellectual property landscape for biosensors in drug discovery likely to evolve in the foreseen future? What are the factors that are likely to influence the evolution of this market? How is the current and future market opportunity likely to be distributed across key segments? The financial opportunity within the biosensors in drug discovery market has been analyzed across the following segments: Type of Biosensor Optical Electrochemical Thermal Others Type of End User Academic / Research Institutes Industry Players Key Geographical Regions North America Europe Asia-Pacific Latin America MENA Rest of the World The report features inputs from eminent industry stakeholders, according to whom, continuous growth of biosensors market for drug discovery applications is primarily driven by the increasing adoption for such products. The report includes detailed transcripts of discussions held with the following experts: Bill Rader (Chief Executive Officer, Efferent Labs) Anne Marie Quinn (Chief Executive Officer, Montana Molecular) Laurent Sabbagh (Associate Director and Head of Biology, Domain Therapeutics). The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its biosensor product portfolio, recent developments and an informed future outlook. Agilent Technologies Axion Biosciences BioNavigations Creoptix  Cytiva Dynamic Biosensors Malvern Panalytical Microvacuum Sartorius Tempo Bioscience Request for Sample: https://www.rootsanalysis.com/reports/global-biosensors-market/request-sample.html   Read Our Latest Blogs: https://www.rootsanalysis.com/blog/womens-digital-health-a-new-era-of-female-healthcare/ https://www.rootsanalysis.com/blog/sustainable-biodegradable-and-eco-friendly-packaging-a-paradigm-shift-in-healthcare-packaging/ https://www.rootsanalysis.com/blog/rising-demand-for-pharmaceutical-secondary-packaging-providers/ https://www.rootsanalysis.com/blog/single-use-technology-a-step-towards-future-transformation/ https://www.rootsanalysis.com/blog/continuous-manufacturing-a-magic-bullet-to-meet-the-demand-for-pharmaceutical-products/   Visit for More Insights: https://www.rootsanalysis.com/reports.html Read Our Latest Press Release: https://www.rootsanalysis.com/press-releases.html Latest Blogs On Healthcare Industry: https://www.rootsanalysis.com/blog/   Our Service Portfolio: Pipeline Tracking | Publication Analysis | Investment Analysis | Market Assessment | Competitive Profiling | Commercial Strategy and Business Development   About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com

Given their low immunogenicity, diversified targets and ability to offer higher biosafety, the adeno-associated viral vectors are actively being evaluated for the development of various therapies for the treatment of chronic diseases and infections  Roots Analysis has announced the addition of “Adeno-Associated Viral Vector Market, 2022-2035” report to its list of offerings. Owing to their unique biology, simple structure and lack of disease correlation, the adeno-associated viral vectors have garnered significant interest within the medical community. In fact, various adeno-associated viral vector-based therapies have been developed for the treatment of multiple indications, including retinitis pigmentosa, cystic fibrosis and Duchenne muscular dystrophy. As a result, the demand for such vectors have increased tremendously, thereby creating lucrative opportunities for the players engaged in the adeno-associated viral vector market.     Key Market Insights More than 550 adeno-associated viral vector-based therapies have been / are being evaluated across different stages of development for the treatment of various disorders Close to 20% of the pipeline candidates are under clinical evaluation; majority (26%) of these candidates are being developed for the treatment of neurological disorders, followed by those being evaluated for the treatment of ophthalmic disorders (21%). 80+ industry stakeholders claim to have the required capability to manufacture adeno-associated viral vectors The market is currently dominated by the presence of various mid-sized industry players (53%); of these 65% of the players possess in-house manufacturing capabilities, whereas 44% of players are contract manufacturers. Get Detailed Report: https://www.rootsanalysis.com/reports/anti-agingtherapeutics-market.html   Over 30 players are involved in the development of adeno-associated viral vector platforms More than 90% of these players offer their technologies for gene therapy, followed by those offering platforms for cell therapy (23%). It is worth mentioning that two technologies can manufacture vectors at all scales of operation, including preclinical, clinical and laboratory. More than 155 clinical trials have been registered for the evaluation of adeno-associated viral vector-based therapies, worldwide The clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 20%, since 2010. Of the total number of trials registered, close to 25% have already been completed, while 46% of the studies are actively recruiting participants. Partnership activity within this domain has increased at a CAGR of ~50%, between 2017 and 2021 More than 60% of the reported deals were established since 2020, with the maximum activity (~50%) being reported in 2021. Majority of the partnerships were established for product development (30%), followed by agreements inked for research and development (15%). Over 4,370 patents have been filed / granted related to adeno-associated viral vectors, since 2017 Close to 35% of these patents were filed / granted in North America, followed by Asia-Pacific (32%). It is worth highlighting that, in addition to the industry players, various non-industry / academic players have also filed patents related to adeno-associated viral vectors; these include University of Pennsylvania, University of Florida and the Research Institute of Nationwide Children's Hospital. More than 50 start-ups have emerged in the last 10 years in the adeno-associated viral vector domain Close to 60% of the start-ups have been established in North America. Among these, more than 95% of the firms are based in the US. This is followed by Europe, accounting for more than 30% of the start-ups focused on adeno-associated viral vectors. North America is anticipated to capture larger share of the adeno-associated viral vector market by 2035 The market will be primarily driven by the manufacturers developing therapies for the treatment of oncological disorders (20%). In addition, by 2035, majority market share of the adeno-associated viral vector-based therapies is anticipated to be dominated by commercial scale of operation (46%), followed by preclinical (40%) and clinical (14%). Request for Customization @ https://www.rootsanalysis.com/reports/antiaging-therapeutics-market/request-customization.html   Key Questions Answered Which adeno-associated viral vector-based therapy candidates are being developed across early and late stages of development? Which disease indications are targeted by such therapies? Who are the leading players (contract service providers and in-house manufacturers) engaged in the development of adeno-associated viral vectors? Which type of adeno-associated viral vector related technologies are presently offered / being developed by the industry players? Which geographies are the most active in conducting clinical trials related to adeno-associated viral vectors? Which partnership models are commonly adopted by industry and non-industry stakeholders? Which companies are likely to partner with adeno-associated viral vector and gene therapy product manufacturers? What are the different initiatives recently undertaken by the start-ups engaged in the development of adeno-associated viral vectors? Which factors are likely to influence the decision of adeno-associated viral vector therapy developers for outsourcing manufacturing operations? How is the current and future market opportunity related to adeno-associated viral vectors likely to be distributed across key market segments? The financial opportunity within the adeno-associated viral vector market has been analysed across the following segments: Type of Therapy Gene Augmentation Immunotherapy Other Therapies Type of Gene Delivery Method Used Ex vivo In vivo Target Therapeutic Area Genetic Disorders Hematological Disorders Infectious Diseases Metabolic Disorders Ophthalmic Disorders Muscle Disorders Neurological Disorders Others Scale of Operation Preclinical Clinical Commercial Application Area Gene Therapy Cell Therapy Vaccines Geographical Regions North America Europe Asia-Pacific MENA Latin America Rest of the World The research also includes detailed profiles of the key players (listed below) engaged in the adeno-associated viral vector market; each profile features an overview of the company, its financial information (if available), details related to its manufacturing facilities and proprietary vector manufacturing technology portfolio, and recent developments and an informed future outlook. Abeona Therapeutics Aldevron Oxford BioMedica Sanofi WuXi AppTec Yposkesi The report features inputs from eminent industry stakeholders, according to whom, the anticipated increase in the demand for gene therapies, is the most prominent driver of the growth of the adeno-associated viral vector market. The report includes detailed transcripts of discussions held with following industry representatives: Arun Srivastava (Professor of Genetics and Chief of Division of Cellular and Molecular Therapy, University of Florida) Abhishek Chatterjee (Professor, Boston College) Adam Lauber (Chief Financial Officer, Andelyn Biosciences) Request        for      Sample: https://www.rootsanalysis.com/reports/anti-agingtherapeutics-market/request-sample.html     Read Our Latest Blogs: https://www.rootsanalysis.com/blog/generic-drugs-rising-opportunity-forindian-pharmaceutical-players/   https://www.rootsanalysis.com/blog/social-media-in-pharmaceuticalmarketing/   https://www.rootsanalysis.com/blog/cancer-stem-cells-a-step-closer-to-thecure/   https://www.rootsanalysis.com/blog/trends-in-human-health-management-ajourney-through-time/    https://www.rootsanalysis.com/blog/genome-editing-future-potential-andethical-concerns/     Visit for More Insights: https://www.rootsanalysis.com/reports.html   Read Our Latest Press Release: https://www.rootsanalysis.com/pressreleases.html   Latest Blogs On Healthcare Industry: https://www.rootsanalysis.com/blog/  Our Service Portfolio: Pipeline Tracking | Publication Analysis | Investment Analysis | Market Assessment | Competitive Profiling | Commercial Strategy and Business Development   About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.  Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com